SC 13G/A | 2021-08-09 | BlackRock Inc. | ALEXION PHARMACEUTICALS, INC. | 0 | 0.0% | EDGAR |
SC 13G/A | 2021-02-16 | PRICE T ROWE ASSOCIATES INC /MD/ | ALEXION PHARMACEUTICALS, INC. | 1,536,173 | 0.7% | EDGAR |
SC 13G/A | 2021-02-12 | STATE STREET CORP | ALEXION PHARMACEUTICALS, INC. | - | 4.9% | EDGAR |
SC 13G/A | 2021-02-10 | VANGUARD GROUP INC | ALEXION PHARMACEUTICALS, INC. | 19,406,768 | 8.9% | EDGAR |
SC 13G/A | 2021-02-08 | FMR LLC | ALEXION PHARMACEUTICALS, INC. | 6,329,881 | 2.9% | EDGAR |
SC 13G/A | 2021-02-05 | BlackRock Inc. | ALEXION PHARMACEUTICALS, INC. | 18,168,276 | 8.3% | EDGAR |
SC 13G/A | 2020-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | ALEXION PHARMACEUTICALS, INC. | 12,105,898 | 5.4% | EDGAR |
SC 13G | 2020-02-13 | STATE STREET CORP | ALEXION PHARMACEUTICALS, INC. | - | 5.1% | EDGAR |
SC 13G/A | 2020-02-12 | VANGUARD GROUP INC | ALEXION PHARMACEUTICALS, INC. | 16,764,417 | 7.6% | EDGAR |
SC 13G/A | 2020-02-05 | BlackRock Inc. | ALEXION PHARMACEUTICALS, INC. | 15,913,371 | 7.2% | EDGAR |
SC 13G/A | 2020-01-10 | FMR LLC | ALEXION PHARMACEUTICALS, INC. | 14,805,724 | 6.7% | EDGAR |
SC 13G/A | 2019-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | ALEXION PHARMACEUTICALS, INC. | 17,672,485 | 7.9% | EDGAR |
SC 13G/A | 2019-02-13 | FMR LLC | ALEXION PHARMACEUTICALS, INC. | 26,510,953 | 11.9% | EDGAR |
SC 13G/A | 2019-02-12 | STATE STREET CORP | ALEXION PHARMACEUTICALS, INC. | - | 4.9% | EDGAR |
SC 13G/A | 2019-02-11 | VANGUARD GROUP INC | ALEXION PHARMACEUTICALS, INC. | 16,221,911 | 7.3% | EDGAR |
SC 13G/A | 2019-02-04 | BlackRock Inc. | ALEXION PHARMACEUTICALS, INC. | 16,231,360 | 7.3% | EDGAR |
SC 13G/A | 2018-11-13 | FMR LLC | ALEXION PHARMACEUTICALS, INC. | 24,813,738 | 11.1% | EDGAR |
SC 13G/A | 2018-06-11 | PRICE T ROWE ASSOCIATES INC /MD/ | ALEXION PHARMACEUTICALS INC | 22,453,384 | 10.0% | EDGAR |
SC 13G/A | 2018-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | ALEXION PHARMACEUTICALS INC | 21,006,788 | 9.4% | EDGAR |
SC 13G/A | 2018-02-13 | FMR LLC | ALEXION PHARMACEUTICALS INC | 17,709,641 | 7.9% | EDGAR |